Mixed stereochemistry macrocycle acts as a helix-stabilizing peptide N-cap
Preprint
- 2 April 2024
- preprint
- Published by American Chemical Society (ACS) in ChemRxiv
Abstract
Interactions between proteins and α-helical peptides are abundant in the human cell. Many of these interactions are linked to disease and have been the focus of drug discovery campaigns. However, the large interfaces formed between multiple turns of α-helix and a binding protein represent a significant challenge to inhibitor discovery. Modified peptides featuring helix-stabilizing macrocycles have shown promise as inhibitors of these interactions. Here, we tested the ability of N-terminal to side-chain thioether-cyclized peptides to inhibit the α-helix binding protein Mcl-1, by screening a trillion-scale peptide library using RaPID technology. The top enriched peptides were lariats, featuring a small, four amino acid N-terminal macrocycle followed by a short linear sequence that resembled the natural α-helical Mcl-1 ligands. These ‘Heliats’ (Helical lariats) bound Mcl-1 with mid-nM affinity, and inhibited the interaction between Mcl-1 and a natural peptide ligand. Macrocyclization was found to stabilize α-helical structures, and significantly contribute to affinity and potency. Yet, the 2nd and 3rd positions within the macrocycle were permissible to sequence variation, so that a minimal macrocyclic motif, of an N-acetylated D-phenylalanine at the 1st position thioether connected a cysteine at the 4th, could be grafted into a natural peptide and stabilize helical conformations. We found that D-stereochemistry is more helix-stabilizing than L- at the 1st position in the motif, as the D-amino acid can utilize polyproline II torsional angles that allow for more optimal intrachain hydrogen bonding. This mixed stereochemistry macrocyclic N-cap is synthetically accessible, requiring only minor modifications to standard solid-phase peptide synthesis, and its compatibility with RaPID peptide screening can provide ready access to helix-focused peptide libraries for de novo inhibitor discovery.Keywords
All Related Versions
Funding Information
- Novo Nordisk Fonden (18OC0032996)
- Novo Nordisk Fonden (14CC0001)
- Novo Nordisk Fonden (19OC0054441)
- Agence Nationale de la Recherche (ANR-14-JITC-2014-003)
- Eusko Jaurlaritza (IT1584-22)
This publication has 47 references indexed in Scilit:
- Discovery and characterization of cyclic peptides selective for the C-terminal bromodomains of BET family proteinsStructure, 2023
- Biophysical Characterization of Pro-apoptotic BimBH3 Peptides Reveals an Unexpected Capacity for Self-AssociationStructure, 2021
- Development of Mcl-1 inhibitors for cancer therapyEuropean Journal of Medicinal Chemistry, 2021
- Helix stabilization by stapled N-capping boxBioorganic Chemistry, 2020
- RNA Display Methods for the Discovery of Bioactive MacrocyclesChemical Reviews, 2018
- Helix Nucleation via Hydrocarbon Cross‐link Mimicking N‐capping BoxBulletin of the Korean Chemical Society, 2016
- Natural Product-Like Macrocyclic N-Methyl-Peptide Inhibitors against a Ubiquitin Ligase Uncovered from a Ribosome-Expressed De Novo LibraryChemistry & Biology, 2011
- SPARTA+: a modest improvement in empirical NMR chemical shift prediction by means of an artificial neural networkJournal of Biomolecular NMR, 2010
- Binding Affinities of Host–Guest, Protein–Ligand, and Protein–Transition‐State ComplexesAngewandte Chemie International Edition, 2003
- α-Helix formation by peptides of defined sequenceBiophysical Chemistry, 1995